Two-Year safety check for promising Alpha-1 lung therapy
NCT ID NCT02796937
Summary
This study aims to gather two more years of safety data for a weekly intravenous treatment in people with lung damage caused by Alpha-1 Antitrypsin Deficiency. It is an extension of a previous trial, enrolling about 290 participants who will receive the treatment for 104 weeks. The main goal is to monitor for any side effects while also checking if the treatment helps maintain lung function and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMPHYSEMA IN ALPHA-1 ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Grifols Investigative Site
Phoenix, Arizona, 85013, United States
-
Grifols Investigative Site
Miami, Florida, 33136, United States
-
Grifols Investigative Site
Wilmington, North Carolina, 28401, United States
-
Grifols Investigative Site
Portland, Oregon, 97239, United States
-
Grifols Investigative Site
Charleston, South Carolina, 29425, United States
-
Grifols Investigative Site
Tyler, Texas, 75708, United States
-
Grifols Investigative Site
Darlinghurst, New South Wales, 2010, Australia
-
Grifols Investigative Site
Adelaide, 5000, Australia
-
Grifols Investigative Site
Chermside, 4032, Australia
-
Grifols Investigative Site
Fitzroy, 3065, Australia
-
Grifols Investigative Site
Nedlands, 6009, Australia
-
Grifols Investigative Site
Halifax, B3H 3A7, Canada
-
Grifols Investigative Site
Toronto, M5T 3A9, Canada
-
Grifols Investigative Site
Arhus C, 8000, Denmark
-
Grifols Investigative Site
Hellerup, 2900, Denmark
-
Grifols Investigative Site
Tallinn, 13419, Estonia
-
Grifols Investigative Site
Turku, 20520, Finland
-
Grifols Investigative Site
Bron, Rhone, 69677, France
-
Grifols Investigative Site
Chisinau, 2025, Moldova
-
Grifols Investigative Site
Auckland, 2025, New Zealand
-
Grifols Investigative Site
Christchurch, 8011, New Zealand
-
Grifols Investigative Site
Hamilton, 3200, New Zealand
-
Grifols Investigative Site
Krakow, 31-066, Poland
-
Grifols Investigative Site
Warsaw, 01-138, Poland
-
Grifols Investigative Site
Barnaul, 656038, Russia
-
Grifols Investigative Site
Gothenburg, 413 45, Sweden
-
Grifols Investigative Site
Malmo, 20502, Sweden
-
Grifols Investigative Site
Stockholm, 11361, Sweden
Conditions
Explore the condition pages connected to this study.